Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Assessment of wheezing frequency and viral etiology on childhood and adolescent asthma risk

To the Editor:

Viral respiratory wheezing illnesses are common in early childhood, and many children who wheeze subsequently develop asthma. In the Childhood Origins of ASThma (COAST) cohort, we previously reported that the development of rhinovirus (RV) wheezing illnesses in infancy and early childhood is the most robust predictor of subsequent asthma development in high-risk children at age 6 years, regardless of aeroallergen sensitization or other risk factors.1 However, a study in a similar high-risk birth cohort recently reported that the number of lower-respiratory episodes in the first 3 years of life, as opposed to a specific viral or bacterial etiology, was associated with asthma risk, and suggested that the specific microbiologic trigger is not important for the risk for later asthma development.2 This discrepancy in the literature is important to address as it may affect how risk for childhood asthma is ascertained; accurate identification of high-risk children may be key in asthma prevention. Therefore, we assessed the contribution of the etiology and frequency of wheezing illnesses on asthma risk in patients from ages 6 to 13 years in the COAST cohort recently reported that the number of lower-respiratory episodes in the first 3 years of life. RV was detected in 49% (227/466) of them. Respiratory viruses were detected in 93% (432/466) of them. Respiratory viruses detected during wheezing illnesses in the first 3 years of life. Respiratory syncytial virus (RSV); RV-A, -B, and -C; influenza types A and B (Flu); parainfluenza virus types 1-4 (PIV); adenovirus (Adv); enteroviruses (EV); OC43, NL63, and 229E (CV); metapneumoviruses (MPV), and bocaviruses (BV). The total is >100% because in some cases more than 1 virus was identified during a wheezing illness.

We next examined the impact of the frequency and viral etiology of wheezing illnesses during the first 3 years of life on subsequent asthma risk. Generalized additive models were fit under 2 scenarios: one that ignored etiology, with a single smooth term for the total number of wheezing illnesses, and one that included etiology, with smooth terms for the total numbers of RV wheezing illnesses and non-RV wheezing illnesses and their interactions. These 2 models were then compared using a likelihood ratio test. At every age, the model that included etiology was significantly more informative for asthma risk than was the model that ignored etiology (6 years, \( P = .03 \); 8 years, \( P = .003 \); 11 years, \( P = .04 \); 13 years, \( P = .01 \). Figure 2). Furthermore, asthma risk was higher with multiple RV wheezing illnesses compared with a single RV wheezing illness (2 or more RV wheezing illnesses compared with 1 RV wheezing illness at years 6, 8, 11, and 13; \( P = .003, .009, .009 \), and .11, respectively).

In this study, the number of RV wheezing episodes in early childhood was most closely associated with asthma risk. These findings support the concept that while the number of wheezing illnesses, irrespective of etiology, is important for asthma risk, the number of RV wheezing illnesses is the most robust asthma predictor. Therefore, both the number and the etiology of viral wheezing episodes in early life are important predictors of the risk for childhood asthma. Thus, the importance of pathogen-specific responses should not be underestimated when considering mechanisms driving disease, as infection with specific pathogens can lead to very different immune responses in the respiratory
Moreover, it is likely that both host factors and viral etiology contribute to the activation of immune pathways driving disease, which are important to identify in order to elucidate effective intervention strategies and/or to modify disease progression in each individual child.

One potential explanation for the discrepancy between these results and the recent report by Bonnelykke et al. relates to differential frequency of viral detection in COAST (93%) compared with that in a similar Copenhagen Prospective Studies on Asthma in Childhood (COPSAC) high-risk cohort (65%). The detection of RV (49% vs 23%) accounts for the majority of the discrepancy. In our viral detection, we initially used a set of primers in seminested PCR that historically identified previously undetected strains of human RV now classified as RV-Cs. Moreover, our molecular typing assay was recently modified based on new sequence information to increase sensitivity and specificity of RV detection. We hypothesize that the molecular techniques utilized in our study more robustly detect RV, including novel RV-C types. Since RV-Cs are closely associated with lower respiratory infection and wheezing, incomplete RV-C detection could lead to an underestimate of how RV infections in early life are related to subsequent asthma. Additionally, the focus on wheezing episodes in COAST versus “troublesome lung symptoms” in COPSAC may also have contributed to the differences in study results.

In conclusion, the findings from our study suggest that viral etiology of early life wheezing and the number of episodes are important to subsequent asthma risk, and that the prevalence of RV wheezing illnesses is an important predictor of asthma development in high-risk children. Additional studies are needed to determine whether these same relationships hold true in unselected birth cohort studies.

Halie M. Anderson, MD
Robert F. Lemanske, Jr, MD
Michael D. Evans, MS
Ronald E. Gangnon, MS, PhD
Tressa Pappas, BS
Kris Grindle, MS
Yury A. Bochkov, PhD
James E. Gern, MD
Daniel J. Jackson, MD

From the Division of Allergy, Immunology and Rheumatology, Department of Pediatrics, and the Department of Biostatistics and Medical Informatics, University of Wisconsin School of Medicine & Public Health, Madison, Wis. E-mail: Henderson@pediatrics.wisc.edu.

Disclosure of potential conflict of interest: The authors declare that they have no relevant conflicts of interest.
Increased immune reactivity to central nervous system–derived naturally presented peptides in patients with active multiple sclerosis

To the Editor:

So far, no unequivocal target of the autoimmune attack in multiple sclerosis (MS) could be identified.1 A novel approach to identify autoantigens was pursued by us, examining which antigens are locally presented in the central nervous system (CNS) of patients with MS. We eluted and identified MHC-bound peptides (in the following text also referred to as the “MHC ligandome”) from the CNS of patients with MS.2 In the present study, we analyzed IFN-γ (the signature cytokine of T H1 cells) responses of PBMCs from 55 patients with MS and 18 from controls when stimulated with some of these naturally presented peptides by ELISPOT (see the Methods section and Table E1 in the article’s Online Repository at www.jacionline.org). Patients with MS taking part in the study had given written informed consent and were clinically very well characterized regarding the disease state.3 We calculated the number of specific IFN-γ–secreting cells in response to a panel of 11 ligandome peptides (see Table E2 in the article’s Online Repository at www.jacionline.org) and 5 additional peptides (see Table E3 in the article’s Online Repository at www.jacionline.org) by subtracting the number of spots in control wells from the number of spots in wells stimulated with antigen.

We chose to assess the number of IFN-γ–secreting cells because there is convincing data of a prominent role of T H1 cells in CNS autoimmunity. In a clinical study with an altered peptide ligand, specific T H1 cells were found to be increased during disease relapses occurring during the treatment.4 Data show a pathogenic role of T H1 cells also in the absence of T H17 cells.5 We did observe specific immune responses in the form of IFN-γ–secreting cells against these naturally presented peptides both in controls and in patients with MS, indicating the presence of specific T cells for these self-peptides in normal T-cell repertoires. When we compared the median frequencies of IFN-γ–secreting PBMCs between the control group and all patients with MS, we did not observe any significant difference (Fig 1, A). We subclassified the MS group into patients with active and inactive disease (Fig 1, B). The difference between the 2 patient groups with MS was significant (P = .021, Mann-Whitney U test). However, the trend toward a higher number of IFN-γ–secreting cells in patients with MS with active disease compared with controls did not reach significance (P = .138, Mann-Whitney U test). Patients with active MS showed a higher positive reaction to the tested ligandome peptides compared with patients with inactive disease or controls (see Fig E1 in this article’s Online Repository at www.jacionline.org). There was a significant difference between patients with active MS and inactive MS (P = .003,